Navigation Links
Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors
Date:6/15/2013

use you are removing the target," said lead author Suzanne Wardell, PhD, a research scientist working in McDonnell's lab.

Many investigators had assumed that once breast cancer cells developed resistance to tamoxifen, they would be resistant to all drugs that target the estrogen receptor, McDonnell explained.

"We discovered that the estrogen receptor is still a good target, even after it resistance to tamoxifen has developed," he said.

The investigators tested a variety of breast cancer cell types, including tamoxifen-sensitive cells that are resistant to the drug lapatinib, another targeted therapy that is used to treat patients with advanced breast cancer whose tumors contain the mutant HER2 gene. These cells had previously been shown to reactivate estrogen signaling in order to acquire drug resistance. In this cell type, bazedoxifene also potently inhibited cell growth.

Paradoxically, in bone tissue, bazedoxifene mimics the action of estrogen, helping protect it from destruction. Because bazedoxifene has already undergone safety and efficacy studies as a treatment for osteoporosis, it may be a viable near-term option for patients with advanced breast cancer whose tumors have become resistant to other treatment options, Wardell reported. In clinical trials, the most often reported side effect was hot flashes in the bazedoxifene treatment groups.


'/>"/>

Contact: Rachel Harrison
rachel.harrison@duke.edu
919-419-5069
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. IOF Worldwide Conference of Osteoporosis Patient Societies opens in Helsinki
2. Program announced for the 4th Asia-Pacific Osteoporosis Meeting in Hong Kong
3. Worlds largest meeting dedicated to osteoporosis and osteoarthritis opens in Rome
4. European Guidance for the diagnosis & management of osteoporosis in postmenopausal women
5. Less than 1 month to start of European Congress on Osteoporosis & Osteoarthritis in Rome
6. 4th Asia-Pacific Osteoporosis Meeting to be led by regions leading bone experts
7. European Congress on Osteoporosis and Osteoarthritis
8. Summit of osteoporosis experts from CIS countries issue 5-point call for action
9. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
10. Launch of the EU large-scale integrating project BlueGenics to combat osteoporosis
11. Register now for the key osteoporosis meeting in the Asia-Pacific region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Valley, NY. (Apr. 23, 2014) People who have ... potential to restore neurological function. However, a study conducted ... issue of Cell Transplantation , but is currently ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group ... cells (PBSCs) injected directly into the brain and a ...
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... term for novels and films which focus on the consequences ... how these fictions serve as a mental laboratory that allows ... imagine other living conditions. , "Global warming is much ... is also a cultural phenomenon in which meaning is being ... see. And there are so many of them now that ...
Breaking Biology News(10 mins):Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... may begin in the womb, researchers from Tel Aviv University ... twin can compromise the health of his twin sister before ... published in the journal Pediatrics, the researchers analyzed the incidence ... twins. When born premature, girls who share the womb with ...
... A recent University of Iowa study reveals a biological link ... women than men are diagnosed with chronic pain and fatigue ... mice, the researchers, led by Kathleen Sluka, Ph.D., professor in ... the UI Roy J. and Lucille A. Carver College of ...
... 2008 The Global Innovation Imperatives (Gii) project ... their first session at the American Chemical Societys ... a joint collaboration between the ACS Committee on ... seeks to combat worldwide health, environmental and societal ...
Cached Biology News:War between the sexes begins before twins' birth, TAU researchers say 2U. Iowa study finds biological link between pain and fatigue 2At ACS' national meeting, global initiative set to tackle water issues 2
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... 14, 2014 As pet owners drew up their lists of ... wrote: "Take better care of my furry companion." Nowadays there are ... top-brand carrying cases to take the little canine or feline darlings ... compelled to buy some pricey toys at the pet store. But ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... - Two Milestones Reached in Zonisamide Patent Portfolio ... Therapeutics,Inc. (Nasdaq: OREX ), a biopharmaceutical company ... nervous system-related disorders, today,announced the initiation of its ... formulation of zonisamide plus olanzapine.,The Phase 2a clinical ...
... 2 Clarient, Inc.,(Nasdaq: CLRT ), a ... pathologists, oncologists and the pharmaceutical industry,today announced that ... an,exclusive interview on WallSt.net,s 3-Minute Press Show., ... company, and the,significance of the company,s latest press ...
... Zevalin only Radioimmunotherapy in U.S. to be Indicated ... for Use ... Inc. (CTI),(Nasdaq and MTA: CTIC) announced today that it has ... and Drug,Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation ...
Cached Biology Technology:Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 2Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 3Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 4[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5
Request Info...
... blotted protein on PVDF membrane or with ... N-terminal sequence of proteins (5-20 residues) can ... HPLC or mono-and bidimensional SDS-PAGE, followed by ... the well known EDMAN degradation method. Pre-treatment ...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
... 5 ml Dynabeads® (4.5 ... BerEP4 against the human epithelial ... molecule). Also available in ... 10e7 MNC in 1 ml ...
Biology Products: